 Patent Application Title |
Patent App Num. |
Date |
| Oligo-aminosaccharide compound | 20110003980 | 20110106 |
| An oligo-aminosaccharide compound formed by binding 3 to 6 saccharides, such as 2,6-diamino-2,6-dideoxy-α-(1→4)-D-glucopyranose oligomers, or a salt thereof, which has high affinity to a double-stranded nucleic acid.
... |
| Photoacid generators for the synthesis of oligo-dna in a polymer matrix | 20100331218 | 20101230 |
| Such compounds are useful, for example, in fabricating arrays of polymers.
... |
| Bifunctional cpg or oligo-/polynucleotide and toxin or enterotoxin containing composition | 20100330101 | 20101230 |
| A bifunctional composition comprising an intracellularly effective immunomodulating nucleic acid component containing at least one immunostimulatory, immunoinhibitory or immunomodulating motif and selected from a mononucleotide, a dinucleotide, an oligonucleotide or a polynucleotide with either a natural phosphodiester backbone or a modified backbone, optionally in combination with a specific antigen, in association with a protein binding to specific receptors on mammalian cell surfaces selected from the group consisting of cholera toxin (CT), the subunit B of CT (CTB), Escherichia coli heat labile enterotoxin (LT), the subunit B of LT (LTB), and proteins or protein derivatives that react with antiserum to CT or LT, bind to GM1 ganglioside, ADP-ribosylates an acceptor protein, or give rise to accumulation of cyclic AMP in target cells, and antibodies or other proteins... |
| Composite containing modified hybride resin based on natural fatty acids | 20100324160 | 20101223 |
| The invention relates to natural fatty acid based hybride resin, modified with reactive monomers, and to a method for preparing it. The invention also relates to the use of the modified natural fatty acid based hybride resin as binding agent especially in water based coatings, glues and composites, and as environmentally friendly wood impregnating agent. The modified natural fatty acid based hybride resin comprises the condensation product of natural fatty acid or natural fatty acid ester, modified with di- or oligo-carboxylic acid or anhydride or half ester, and natural fatty acid based alkyd resin.
... |
| Method for the treatment of a sample containing biomolecules | 20100323363 | 20101223 |
| The invention generally provides a method for the sample preparation for a subsequent preparation, processing or analysis method of a sample containing an at least one species of nucleic acid and/or one species of protein, whereby the method comprises the following steps: A) providing a sample which contains at least one species of a nucleic acid and/or of a protein, B) contacting the sample with a fluid or solid composition to produce a fluid sample preparation, whereby the composition contains at least a nitrogenous compound, which is selected from the group consisting of a) polyamines, b) amino acids, and oligo- and polypeptides, c) nitrogenous heterocyclic compounds, including homo- oder heteropolymeres, which comprise these nitrogenous compounds, d) amines of the type R1R2NR3, whereby R1, R2 and R3... |
Subscribe to updates on this page: Oligo- RSS  |
| Composition and method for the treatment of diseases affected by a peptide receptor | 20100317570 | 20101216 |
| The present invention includes peptidomimetic compound compositions and methods of making and using peptidomimetic compounds to modulate the activity of a peptide receptor for the treatment of one or more of hyperglycemia, insulin resistance, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia or other symptoms that relate to the function of the targeted receptor. The peptidomimetic includes an oligo-benzamide compound having at least three optionally substituted benzamides.
... |
| Growth factor complexes and modulation of cell migration and growth | 20100303884 | 20101202 |
| Isolated protein complexes are provided comprising growth factors such as IGF-I, IGF-II, EGF, bFGF, KGF, VEGF or PDGF, or at least domains thereof that enable binding to and activation of both a growth factor receptor, and an integrin receptor-binding domain of vitronectin or fibronectin. These protein complexes may be in the form of oligo-protein complexes or single, synthetic proteins where the growth factor and vitronectin or fibronectin sequences are joined by a linker sequence. In particular forms, vitronectin or fibronectin sequences do not include a heparin binding domain and/or polyanionic domain. Also provided are uses of these protein complexes for stimulating or inducing cell migration and/or proliferation which may have use in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement and skin... |
| Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions | 20100303782 | 20101202 |
| A probiotic composition including the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium. The composition may further include a carrier medium, such as fructo-oligo-saccharides (FOS), as incorporated in a dose form such as a pill, capsule, powder or sachet. The compositions of the disclosure may be usefully employed as health or nutritional supplements, food additives, or therapeutic agents for combating a wide variety of physiological disorders, such as irritable bowel syndrome, autism, and fibromyalgia.
... |
| Use of modified oligo-b-(1,3)-glucans for treating diseases of the immune system, oligo-b- (1,3v-glucan-(1,3)- mannose, oligo-b-(1,3)-glucan-(1,3)- mannitol and derivatives thereof, methods for preparing them and medicaments containing them | 20100286388 | 20101111 |
| The present invention relates to the use of at least one compound of formula (I) or (II), in which R1 is H and n is an integer from 2 to 10, for the preparation of a medicament for treating diseases chosen from the group comprising tumour, cancer, viral disease, bacterial disease, fungal disease, disease of the immune system, auto-immune disease or disease linked to a deficiency in immunostimulation, in human beings and warm-blooded animals. The invention also relates to new products having a mannose or mannitol termination as well as a method for preparing them.
... |
| Microrna and messenger rna detection on arrays | 20100209932 | 20100819 |
| The present teachings provide methods for reverse transcribing, and detecting, a plurality of small nucleic acids such as micro RNAs, from the same reaction mixture as a plurality of messenger RNAs. High levels of multiplexing are provided by the use of a plurality of zip-coded stem-loop reverse transcription primers, along with an oligo-dT-promoter-containing reverse transcription primer, in the same reverse transcription reaction mixture. The resulting products can be amplified in an in vitro transcription reaction, and detected on a solid support such as an array. The present teachings also provide compositions, kits, and devices for performing and detecting the reverse transcription reactions described herein.
... |
| Method for the treatment of a sample containing biomolecules | 20100209912 | 20100819 |
| The invention generally provides a method for the sample preparation for a subsequent preparation, processing or analysis method of a sample containing an at least one species of nucleic acid and/or one species of protein, whereby the method comprises the following steps: A) providing a sample which contains at least one species of a nucleic acid and/or of a protein, B) contacting the sample with a fluid or solid composition to produce a fluid sample preparation, whereby the composition contains at least a nitrogenous compound, which is selected from the group consisting of a) polyamines, b) amino acids, and oligo- and polypeptides, c) nitrogenous heterocyclic compounds, including homo- oder heteropolymers, which comprise these nitrogenous compounds, d) amines of the type R1R2NR3, whereby R1, R2 and R3... |
| Use of gene variants of the human meis1, btbd9, map2k5, lbxcor1, ptprd or a2bp1 gene for diagnostic and therapeutic approaches to restless legs syndrome (rls) | 20100202972 | 20100812 |
| The present invention relates to an oligo- or polynucleotide which can be used in the diagnosis and therapy of restless legs syndrome (RLS). Furthermore, the invention relates to methods of diagnosing a predisposition for or RLS and a method for selecting a therapy to prevent and treat RLS. Moreover, a method for determining the dose of a drug used for treating a patient suffering from RLS and a method to test the efficacy of a drug used for treating RLS in treating other dopaminergic diseases, sleep disorders or spinocerebellar ataxias as well as the use of a drug effective in treating RLS for testing the efficacy of said drug in treating other dopaminergic diseases, sleep disorders or spinocerebellar ataxias. The invention also envisages methods of identifying... |
| Protective hydrocolloid for active ingredients | 20100197568 | 20100805 |
| Partially deamidated rice endosperm protein or rice endosperm protein which is partially conjugated with mono-, di-, oligo- or polysaccharides is used as novel protective hydrocolloid for fat-soluble active ingredients and/or fat-soluble colorants. The present invention further includes compositions comprising that rice endosperm protein and at least one fat-soluble active ingredient/colorant, as well as their manufacture, that rice endosperm protein itself and its manufacture. These compositions are used for the enrichment, fortification and/or coloration of food, beverages, animal feed, personal care or pharmaceutical compositions. The present invention is directed to theses uses and to food, beverages, animal feed, personal care and pharmaceutical compositions containing such a rice endosperm protein and such a composition, respectively.
... |
Subscribe to updates on this page: Oligo- RSS |
| Heat stable nutritional beverage and method of preparing it | 20100196559 | 20100805 |
| A heat stable nutritional beverage having a pH of 6.6-8.2 comprising 5-12% w/w whey protein is obtained by incorporating 4-16% w/w of at least one sugar selected from di-oligo- and polysaccharides, wherein at least one monosaccharide is other than glucose.
... |
| Composition and method to stimulate growth and defense against pathogens in plants | 20100173779 | 20100708 |
| An aqueous composition to stimulate growth and defense against pathogens and other favorable productive properties in plants, including an oligo-carrageenan selected from kappa 1, kappa 2, lambda or iota oligo-carrageenans. Also, a method of spraying said the composition over the leaves of the plants and its use to stimulate defense against tobacco mosaic virus (TMV) and increase the height, the foliar biomass and the number of leaves in a plant. Also including a preparation method of the composition.
... |
| Catalysis of the cis/trans-isomerisation of secondary amide peptide compounds | 20100160175 | 20100624 |
| The present invention is based on the finding that the cis/trans isomerisation of secondary amide peptide bonds in oligo- and polypeptides can be catalytically promoted. This catalysis is effected by enzymes which are hereinafter called “secondary amide peptide bond cis/trans isomerases (APIases). It can be assumed that the APIase activity plays a central role in a number of pathophysiological processes. Thus, the invention relates to pharmaceutical compositions comprising substances which inhibit APIase activity.
... |
| Oligo-guluronate and galacturonate compositions | 20100152122 | 20100617 |
| The invention provides a pharmaceutical composition comprising a macromolecular drug and an oligoguluronate or oligogalacturonate, e.g., having a number average degree of polymerization in the range 5 to 18, a guluronate (or galacturonate) fraction (FG) of at least 0.80, a mannuronate fraction (FM) of no more than 0.20, and having at least 95% mole with a degree of polymerization less than 20. The composition may be used in a method of treatment which comprises administering the composition to a mucosal surface in a human or non-human vertebrate subject.
... |
| Growth factor complexes and modulation of cell migration and growth | 20100143442 | 20100610 |
| Isolated protein complexes are provided comprising growth factors such as IGF-I, IGF-II, VEGF or PDGF, or at least domains thereof that enable binding to and activation of both a growth factor receptor, and an integrin receptor-binding domain of vitronectin or fibronectin. These protein complexes may be in the form of oligo-protein complexes or single, synthetic proteins where the growth factor and vitronectin or fibronectin sequences are joined by a linker sequence. In particular forms, vitronectin or fibronectin sequences do not include a heparin binding domain and/or polyanionic domain. Also provided are uses of these protein complexes for stimulating or inducing cell migration and/or proliferation which may have use in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement and skin replenishment and treatment... |
| Aqueous oligo- and polyester formulations | 20100098655 | 20100422 |
| Aqueous formulations of soil release polyesters are claimed, which comprise from 50 to 90% by weight of soil release polyester and from 0.1 to 40% by weight of a phosphonic acid or of a phosphonate. The addition of the phosphonic acid or of the phosphonate allows the preparation of formulations of the soil release polyesters which are stable and have a low viscosity.
... |
| Preparation of a therapeutic composition | 20100080820 | 20100401 |
| Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system comprises a unique peptide having 31 amino acids and another unique peptide having 21 amino acids and connected with an oligo-nucleotide through a diphosphodiester or diphosphodithioate ester linkage. The composition has a light absorption spectrum with typical absorption ratios of 1.998 at 260 mn/280 nm and 1.359 at 260 nm/230 nm.
... |
| Alcohol free formulation of argatroban | 20100076019 | 20100325 |
| An aqueous formulation of argatroban and of related compounds is disclosed along with a reconstitutable formulation, each of which is substantially, if not totally alcohol free. The formulations are also substantially free, if not totally free, of mono-, di-, and oligo-saccharides. An especially preferred embodiment is a ready-to-use 1 mg/ml injectable dosage form having argatroban, lactobionic acid, and methionine.
... |
| Nutritional products comprising saccharide oligomers | 20100069327 | 20100318 |
| Indigestible oligosaccharides having a molecular weight of 450 Da to 3700 Da are used for the improvement of insulin resistance, the prevention of post-prandial glycaemic dip, and/or the decrease of the post-prandial glucose response of a meal, which is consumed within 72 hours after the consumption of the first product. The oligo-saccharides are especially galacto-oligosaccharides, and are advantageously administered a few hours prior to having the meal.
... |
| Oligo- or polyamines as oxidation stabilizers for biofuel oils | 20100064576 | 20100318 |
| The use of oligo- or polyamines which have a number-average molecular weight of from 46 to 70 000 and are free of phenolic hydroxyl groups for increasing the oxidation stability of biofuel oils based on fatty acid esters, or of mixtures of such biofuel oils with middle distillates of fossil origin and/or of vegetable and/or animal origin, which are essentially hydrocarbon mixtures and are free of fatty acid esters.
... |
| Identifying and counting proteins in a sample | 20100062538 | 20100311 |
| The proteins in a cell are preferably proteolytically cleaved and chemically attached to another peptide of unique and known sequence. In one embodiment of the invention, peptide-linker-peptide triplets are synthesized with linker molecules such as polyhistidine. In a more preferred embodiment of the invention, peptide-mass differentiated group (MDG) constructs are synthesized. The MDG's may be obtained from a library of oligo-N(K)-peptides synthesized on resin beads, wherein N is the length of the peptides (with a default value of 4) and K is the number of alternative amino acids (with a default value of 10) at each position. Coupling between given peptides and linkers or MDG's creates recombinants with different overall masses that migrate separately in chromatographic separations. The peptides-linker/MGD's recombinants may be purified and sequenced by... |
| Urinary immunochromatographic multiparameter detection cup | 20100047799 | 20100225 |
| The present invention refers to an immuno-chromatographic detection cup and its use for simultaneously detecting at least one antigen, e.g. tuberculosis antigen, malaria antigen and pneumonia antigen, and at least one antibody, e.g. HIV antibody, HCV antibody and H. pylori antibody, in a urine sample. The urinary detection cup comprises (a) a sample-collecting container; (b) a conjugate releasing pad comprising a gold labelled antibody X and an oligo-nucleotide linked antibody X′, wherein both antibodies are directed against the same antigen, and a gold labelled antigen Y and an oligo-nucleotide linked antigen Y′, wherein both antigens are recognized by the same antibody; (c) a test means inside the container separated from the conjugate releasing pad, which test means comprises a region comprising an oligo-nucleotide complementary to the... |
| High-performance chromatographic columns containing organic or composite polymeric monolithic supports and method for their preparation | 20100038298 | 20100218 |
| The invention concerns high-performance chromatographic columns containing polymeric monolithic supports with continuous bimodal porosity, suitable for the separation and/or purification of organic compounds of low, medium and high molecular weight, and bio-organic compounds such as peptides, proteins, oligo- and polynucleotides, oligo- and polysaccharides. The proposed columns include a hollow tubular support made of silica-based amorphous material or internally lined with such material, containing a monolithic stationary phase having a continuous, porous and rigid polymeric structure, wherein such stationary phase covalently bonds onto the internal walls of the said hollow tubular support. The chromatographic efficiency of the column is greater than 50,000 plates per metre. The invention also concerns methods for preparing such monolithic columns with gamma radiation-induced polymerization processes.
... |
| Pigment concentrate | 20100010150 | 20100114 |
| Non-aqueous pigment concentrate comprising one or more pigments, one or more dispersants, and at least one resin, characterized in that the resin is a polyester comprising at least one oligo-ester building block with a hydrophobic tail linked thereto, wherein the hydrophobic tail is selected from the group consisting of: (a) branched hydrocarbons, (b) hydrocarbons containing a cyclic group, and (c) linear hydrocarbons, provided that when said linear hydrocarbon is linked to the oligo-ester building block via an ester group, the linear hydrocarbon contains 3 to 12 carbon atoms.
... |
| Oligo-and poly-carbonates terminated with silicon containing groups as surface modifiers | 20100010135 | 20100114 |
| The instant invention relates to new compounds of the formula I wherein the general symbols are as defined in claim 1 and R1 and R2 are each independently of the other a silicon containing group. These new compounds of the formula I are useful as reducers of surface energy for organic materials such as polycarbonates, polyesters or polyketones or their mixtures, blends or alloys. Polymers with such a reduced surface energy possess an “easy to clean”, “self-cleaning” “antisoiling”, “soil-release” “antigraffiti”, “oil resistance”, “solvent resistance”, “chemical resistance”, “self lubricating”, “scratch resistance”, “low moisture absorption”, “dirt pickup resistance”, “slip properties” and “hydrophobic surface”; and antiadhesion properties against proteins and against microorganism such as for example bacteria, fungi and algae.
... |
| Oligo-aminosaccharide compound | 20110003980 | 20110106 |
| An oligo-aminosaccharide compound formed by binding 3 to 6 saccharides, such as 2,6-diamino-2,6-dideoxy-α-(1→4)-D-glucopyranose oligomers, or a salt thereof, which has high affinity to a double-stranded nucleic acid.
... |
| Photoacid generators for the synthesis of oligo-dna in a polymer matrix | 20100331218 | 20101230 |
| Such compounds are useful, for example, in fabricating arrays of polymers.
... |
| Bifunctional cpg or oligo-/polynucleotide and toxin or enterotoxin containing composition | 20100330101 | 20101230 |
| A bifunctional composition comprising an intracellularly effective immunomodulating nucleic acid component containing at least one immunostimulatory, immunoinhibitory or immunomodulating motif and selected from a mononucleotide, a dinucleotide, an oligonucleotide or a polynucleotide with either a natural phosphodiester backbone or a modified backbone, optionally in combination with a specific antigen, in association with a protein binding to specific receptors on mammalian cell surfaces selected from the group consisting of cholera toxin (CT), the subunit B of CT (CTB), Escherichia coli heat labile enterotoxin (LT), the subunit B of LT (LTB), and proteins or protein derivatives that react with antiserum to CT or LT, bind to GM1 ganglioside, ADP-ribosylates an acceptor protein, or give rise to accumulation of cyclic AMP in target cells, and antibodies or other proteins... |
| Composite containing modified hybride resin based on natural fatty acids | 20100324160 | 20101223 |
| The invention relates to natural fatty acid based hybride resin, modified with reactive monomers, and to a method for preparing it. The invention also relates to the use of the modified natural fatty acid based hybride resin as binding agent especially in water based coatings, glues and composites, and as environmentally friendly wood impregnating agent. The modified natural fatty acid based hybride resin comprises the condensation product of natural fatty acid or natural fatty acid ester, modified with di- or oligo-carboxylic acid or anhydride or half ester, and natural fatty acid based alkyd resin.
... |
| Method for the treatment of a sample containing biomolecules | 20100323363 | 20101223 |
| The invention generally provides a method for the sample preparation for a subsequent preparation, processing or analysis method of a sample containing an at least one species of nucleic acid and/or one species of protein, whereby the method comprises the following steps: A) providing a sample which contains at least one species of a nucleic acid and/or of a protein, B) contacting the sample with a fluid or solid composition to produce a fluid sample preparation, whereby the composition contains at least a nitrogenous compound, which is selected from the group consisting of a) polyamines, b) amino acids, and oligo- and polypeptides, c) nitrogenous heterocyclic compounds, including homo- oder heteropolymeres, which comprise these nitrogenous compounds, d) amines of the type R1R2NR3, whereby R1, R2 and R3... |
| Composition and method for the treatment of diseases affected by a peptide receptor | 20100317570 | 20101216 |
| The present invention includes peptidomimetic compound compositions and methods of making and using peptidomimetic compounds to modulate the activity of a peptide receptor for the treatment of one or more of hyperglycemia, insulin resistance, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia or other symptoms that relate to the function of the targeted receptor. The peptidomimetic includes an oligo-benzamide compound having at least three optionally substituted benzamides.
... |
| Growth factor complexes and modulation of cell migration and growth | 20100303884 | 20101202 |
| Isolated protein complexes are provided comprising growth factors such as IGF-I, IGF-II, EGF, bFGF, KGF, VEGF or PDGF, or at least domains thereof that enable binding to and activation of both a growth factor receptor, and an integrin receptor-binding domain of vitronectin or fibronectin. These protein complexes may be in the form of oligo-protein complexes or single, synthetic proteins where the growth factor and vitronectin or fibronectin sequences are joined by a linker sequence. In particular forms, vitronectin or fibronectin sequences do not include a heparin binding domain and/or polyanionic domain. Also provided are uses of these protein complexes for stimulating or inducing cell migration and/or proliferation which may have use in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement and skin... |
| Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions | 20100303782 | 20101202 |
| A probiotic composition including the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium. The composition may further include a carrier medium, such as fructo-oligo-saccharides (FOS), as incorporated in a dose form such as a pill, capsule, powder or sachet. The compositions of the disclosure may be usefully employed as health or nutritional supplements, food additives, or therapeutic agents for combating a wide variety of physiological disorders, such as irritable bowel syndrome, autism, and fibromyalgia.
... |
| Use of modified oligo-b-(1,3)-glucans for treating diseases of the immune system, oligo-b- (1,3v-glucan-(1,3)- mannose, oligo-b-(1,3)-glucan-(1,3)- mannitol and derivatives thereof, methods for preparing them and medicaments containing them | 20100286388 | 20101111 |
| The present invention relates to the use of at least one compound of formula (I) or (II), in which R1 is H and n is an integer from 2 to 10, for the preparation of a medicament for treating diseases chosen from the group comprising tumour, cancer, viral disease, bacterial disease, fungal disease, disease of the immune system, auto-immune disease or disease linked to a deficiency in immunostimulation, in human beings and warm-blooded animals. The invention also relates to new products having a mannose or mannitol termination as well as a method for preparing them.
... |
| Microrna and messenger rna detection on arrays | 20100209932 | 20100819 |
| The present teachings provide methods for reverse transcribing, and detecting, a plurality of small nucleic acids such as micro RNAs, from the same reaction mixture as a plurality of messenger RNAs. High levels of multiplexing are provided by the use of a plurality of zip-coded stem-loop reverse transcription primers, along with an oligo-dT-promoter-containing reverse transcription primer, in the same reverse transcription reaction mixture. The resulting products can be amplified in an in vitro transcription reaction, and detected on a solid support such as an array. The present teachings also provide compositions, kits, and devices for performing and detecting the reverse transcription reactions described herein.
... |
| Method for the treatment of a sample containing biomolecules | 20100209912 | 20100819 |
| The invention generally provides a method for the sample preparation for a subsequent preparation, processing or analysis method of a sample containing an at least one species of nucleic acid and/or one species of protein, whereby the method comprises the following steps: A) providing a sample which contains at least one species of a nucleic acid and/or of a protein, B) contacting the sample with a fluid or solid composition to produce a fluid sample preparation, whereby the composition contains at least a nitrogenous compound, which is selected from the group consisting of a) polyamines, b) amino acids, and oligo- and polypeptides, c) nitrogenous heterocyclic compounds, including homo- oder heteropolymers, which comprise these nitrogenous compounds, d) amines of the type R1R2NR3, whereby R1, R2 and R3... |
| Use of gene variants of the human meis1, btbd9, map2k5, lbxcor1, ptprd or a2bp1 gene for diagnostic and therapeutic approaches to restless legs syndrome (rls) | 20100202972 | 20100812 |
| The present invention relates to an oligo- or polynucleotide which can be used in the diagnosis and therapy of restless legs syndrome (RLS). Furthermore, the invention relates to methods of diagnosing a predisposition for or RLS and a method for selecting a therapy to prevent and treat RLS. Moreover, a method for determining the dose of a drug used for treating a patient suffering from RLS and a method to test the efficacy of a drug used for treating RLS in treating other dopaminergic diseases, sleep disorders or spinocerebellar ataxias as well as the use of a drug effective in treating RLS for testing the efficacy of said drug in treating other dopaminergic diseases, sleep disorders or spinocerebellar ataxias. The invention also envisages methods of identifying... |
| Protective hydrocolloid for active ingredients | 20100197568 | 20100805 |
| Partially deamidated rice endosperm protein or rice endosperm protein which is partially conjugated with mono-, di-, oligo- or polysaccharides is used as novel protective hydrocolloid for fat-soluble active ingredients and/or fat-soluble colorants. The present invention further includes compositions comprising that rice endosperm protein and at least one fat-soluble active ingredient/colorant, as well as their manufacture, that rice endosperm protein itself and its manufacture. These compositions are used for the enrichment, fortification and/or coloration of food, beverages, animal feed, personal care or pharmaceutical compositions. The present invention is directed to theses uses and to food, beverages, animal feed, personal care and pharmaceutical compositions containing such a rice endosperm protein and such a composition, respectively.
... |
| Heat stable nutritional beverage and method of preparing it | 20100196559 | 20100805 |
| A heat stable nutritional beverage having a pH of 6.6-8.2 comprising 5-12% w/w whey protein is obtained by incorporating 4-16% w/w of at least one sugar selected from di-oligo- and polysaccharides, wherein at least one monosaccharide is other than glucose.
... |
| Composition and method to stimulate growth and defense against pathogens in plants | 20100173779 | 20100708 |
| An aqueous composition to stimulate growth and defense against pathogens and other favorable productive properties in plants, including an oligo-carrageenan selected from kappa 1, kappa 2, lambda or iota oligo-carrageenans. Also, a method of spraying said the composition over the leaves of the plants and its use to stimulate defense against tobacco mosaic virus (TMV) and increase the height, the foliar biomass and the number of leaves in a plant. Also including a preparation method of the composition.
... |
| Catalysis of the cis/trans-isomerisation of secondary amide peptide compounds | 20100160175 | 20100624 |
| The present invention is based on the finding that the cis/trans isomerisation of secondary amide peptide bonds in oligo- and polypeptides can be catalytically promoted. This catalysis is effected by enzymes which are hereinafter called “secondary amide peptide bond cis/trans isomerases (APIases). It can be assumed that the APIase activity plays a central role in a number of pathophysiological processes. Thus, the invention relates to pharmaceutical compositions comprising substances which inhibit APIase activity.
... |
| Oligo-guluronate and galacturonate compositions | 20100152122 | 20100617 |
| The invention provides a pharmaceutical composition comprising a macromolecular drug and an oligoguluronate or oligogalacturonate, e.g., having a number average degree of polymerization in the range 5 to 18, a guluronate (or galacturonate) fraction (FG) of at least 0.80, a mannuronate fraction (FM) of no more than 0.20, and having at least 95% mole with a degree of polymerization less than 20. The composition may be used in a method of treatment which comprises administering the composition to a mucosal surface in a human or non-human vertebrate subject.
... |
| Growth factor complexes and modulation of cell migration and growth | 20100143442 | 20100610 |
| Isolated protein complexes are provided comprising growth factors such as IGF-I, IGF-II, VEGF or PDGF, or at least domains thereof that enable binding to and activation of both a growth factor receptor, and an integrin receptor-binding domain of vitronectin or fibronectin. These protein complexes may be in the form of oligo-protein complexes or single, synthetic proteins where the growth factor and vitronectin or fibronectin sequences are joined by a linker sequence. In particular forms, vitronectin or fibronectin sequences do not include a heparin binding domain and/or polyanionic domain. Also provided are uses of these protein complexes for stimulating or inducing cell migration and/or proliferation which may have use in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement and skin replenishment and treatment... |
| Aqueous oligo- and polyester formulations | 20100098655 | 20100422 |
| Aqueous formulations of soil release polyesters are claimed, which comprise from 50 to 90% by weight of soil release polyester and from 0.1 to 40% by weight of a phosphonic acid or of a phosphonate. The addition of the phosphonic acid or of the phosphonate allows the preparation of formulations of the soil release polyesters which are stable and have a low viscosity.
... |
| Preparation of a therapeutic composition | 20100080820 | 20100401 |
| Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system comprises a unique peptide having 31 amino acids and another unique peptide having 21 amino acids and connected with an oligo-nucleotide through a diphosphodiester or diphosphodithioate ester linkage. The composition has a light absorption spectrum with typical absorption ratios of 1.998 at 260 mn/280 nm and 1.359 at 260 nm/230 nm.
... |
| Alcohol free formulation of argatroban | 20100076019 | 20100325 |
| An aqueous formulation of argatroban and of related compounds is disclosed along with a reconstitutable formulation, each of which is substantially, if not totally alcohol free. The formulations are also substantially free, if not totally free, of mono-, di-, and oligo-saccharides. An especially preferred embodiment is a ready-to-use 1 mg/ml injectable dosage form having argatroban, lactobionic acid, and methionine.
... |
| Nutritional products comprising saccharide oligomers | 20100069327 | 20100318 |
| Indigestible oligosaccharides having a molecular weight of 450 Da to 3700 Da are used for the improvement of insulin resistance, the prevention of post-prandial glycaemic dip, and/or the decrease of the post-prandial glucose response of a meal, which is consumed within 72 hours after the consumption of the first product. The oligo-saccharides are especially galacto-oligosaccharides, and are advantageously administered a few hours prior to having the meal.
... |
| Oligo- or polyamines as oxidation stabilizers for biofuel oils | 20100064576 | 20100318 |
| The use of oligo- or polyamines which have a number-average molecular weight of from 46 to 70 000 and are free of phenolic hydroxyl groups for increasing the oxidation stability of biofuel oils based on fatty acid esters, or of mixtures of such biofuel oils with middle distillates of fossil origin and/or of vegetable and/or animal origin, which are essentially hydrocarbon mixtures and are free of fatty acid esters.
... |
| Identifying and counting proteins in a sample | 20100062538 | 20100311 |
| The proteins in a cell are preferably proteolytically cleaved and chemically attached to another peptide of unique and known sequence. In one embodiment of the invention, peptide-linker-peptide triplets are synthesized with linker molecules such as polyhistidine. In a more preferred embodiment of the invention, peptide-mass differentiated group (MDG) constructs are synthesized. The MDG's may be obtained from a library of oligo-N(K)-peptides synthesized on resin beads, wherein N is the length of the peptides (with a default value of 4) and K is the number of alternative amino acids (with a default value of 10) at each position. Coupling between given peptides and linkers or MDG's creates recombinants with different overall masses that migrate separately in chromatographic separations. The peptides-linker/MGD's recombinants may be purified and sequenced by... |
| Urinary immunochromatographic multiparameter detection cup | 20100047799 | 20100225 |
| The present invention refers to an immuno-chromatographic detection cup and its use for simultaneously detecting at least one antigen, e.g. tuberculosis antigen, malaria antigen and pneumonia antigen, and at least one antibody, e.g. HIV antibody, HCV antibody and H. pylori antibody, in a urine sample. The urinary detection cup comprises (a) a sample-collecting container; (b) a conjugate releasing pad comprising a gold labelled antibody X and an oligo-nucleotide linked antibody X′, wherein both antibodies are directed against the same antigen, and a gold labelled antigen Y and an oligo-nucleotide linked antigen Y′, wherein both antigens are recognized by the same antibody; (c) a test means inside the container separated from the conjugate releasing pad, which test means comprises a region comprising an oligo-nucleotide complementary to the... |
| High-performance chromatographic columns containing organic or composite polymeric monolithic supports and method for their preparation | 20100038298 | 20100218 |
| The invention concerns high-performance chromatographic columns containing polymeric monolithic supports with continuous bimodal porosity, suitable for the separation and/or purification of organic compounds of low, medium and high molecular weight, and bio-organic compounds such as peptides, proteins, oligo- and polynucleotides, oligo- and polysaccharides. The proposed columns include a hollow tubular support made of silica-based amorphous material or internally lined with such material, containing a monolithic stationary phase having a continuous, porous and rigid polymeric structure, wherein such stationary phase covalently bonds onto the internal walls of the said hollow tubular support. The chromatographic efficiency of the column is greater than 50,000 plates per metre. The invention also concerns methods for preparing such monolithic columns with gamma radiation-induced polymerization processes.
... |
| Pigment concentrate | 20100010150 | 20100114 |
| Non-aqueous pigment concentrate comprising one or more pigments, one or more dispersants, and at least one resin, characterized in that the resin is a polyester comprising at least one oligo-ester building block with a hydrophobic tail linked thereto, wherein the hydrophobic tail is selected from the group consisting of: (a) branched hydrocarbons, (b) hydrocarbons containing a cyclic group, and (c) linear hydrocarbons, provided that when said linear hydrocarbon is linked to the oligo-ester building block via an ester group, the linear hydrocarbon contains 3 to 12 carbon atoms.
... |
| Oligo-and poly-carbonates terminated with silicon containing groups as surface modifiers | 20100010135 | 20100114 |
| The instant invention relates to new compounds of the formula I wherein the general symbols are as defined in claim 1 and R1 and R2 are each independently of the other a silicon containing group. These new compounds of the formula I are useful as reducers of surface energy for organic materials such as polycarbonates, polyesters or polyketones or their mixtures, blends or alloys. Polymers with such a reduced surface energy possess an “easy to clean”, “self-cleaning” “antisoiling”, “soil-release” “antigraffiti”, “oil resistance”, “solvent resistance”, “chemical resistance”, “self lubricating”, “scratch resistance”, “low moisture absorption”, “dirt pickup resistance”, “slip properties” and “hydrophobic surface”; and antiadhesion properties against proteins and against microorganism such as for example bacteria, fungi and algae.
... |
| Fabrication method of micro-optical elements using photoimageable hybrid materials | 20090311441 | 20091217 |
| The present invention provides with a method for fabricating micro- optical elements comprising: forming a photoimageable hybrid coating layer containing oligo-siloxane containing a polymerizable organic functional group, a photoactive monomer capable of forming a polymer or/and a photochemical initiator monomer initiating polymerization by forming a dimer at the time of illuminating a light on a substrate; and forming a micro-optical element having the structure of a desired shape by illuminating a light on the photoimageable hybrid coating layer.
... |
| Oligomeric compounds which form a semiconductor layer | 20090283723 | 20091119 |
| wherein L represents a linear conjugated oligomeric chain; wherein each RA and each RB independently represents a moiety selected from the group consisting of linear or branched C2-C20-alkylene radicals, C3-C8-cycloalkylene radicals, mono- or polyunsaturated C2-C20-alkenylene radicals, C2-C20-oxyalkylene radicals, C2-C20-aralkylene radicals or C2-C20-oligo- or C2-C20-polyether radicals; wherein XA and XB each independently represents a moiety selected from optionally substituted vinyl groups, chlorine, iodine, hydroxyl, alkoxy groups having 1 to 3 carbon atoms, alkoxysilyl groups, silyl groups, chlorosilyl groups, siloxane groups, carboxyl groups, methyl or ethyl carbonate groups, aldehyde groups, methylcarbonyl groups, amino groups, amido groups, sulphone groups, sulphonic acid groups, halosulphonyl groups, sulphonate groups, phosphonic acid groups, phosphonate groups, trichloromethyl, tribromomethyl, cyanate groups, isocyanate groups, thiocyanate groups, isothiocyanate groups, cyano groups, nitro groups and H; wherein each... |
| Coating material, process for preparing it, and its use for producing firmly adhering color and/or effect coatings | 20090281208 | 20091112 |
| Disclosed herein is a liquid coating material curable with actinic radiation, substantially or entirely free from organic solvents, comprising (A) at least two compounds of general formula X—O—Y(—OH)-Z-Gr wherein X is a C6-C14 aromatic radical, C5-C20 heterocyclic aromatic radical or C6-C30 alkyl radical, Y is a trivalent organic radical, Z is a linking functional group, and Gr is an organic radical comprising one group which can be activated with actinic radiation; with the proviso that at least one of the two compounds (A) comprises aromatic or heterocyclic aromatic radical X and at least one comprises alkyl radical X; (B) oligo- and polyurethanes and/or oligo- and polyesters comprising two or three groups which can be activated with actinic radiation; (C) color and/or effect pigments; (D) waxes; (E)... |
| Coating material, process for preparing it, and its use for producing firmly adhering color and/or effect coatings | 20090281208 | 20091112 |
| Disclosed herein is a liquid coating material curable with actinic radiation, substantially or entirely free from organic solvents, comprising (A) at least two compounds of general formula X—O—Y(—OH)-Z-Gr wherein X is a C6-C14 aromatic radical, C5-C20 heterocyclic aromatic radical or C6-C30 alkyl radical, Y is a trivalent organic radical, Z is a linking functional group, and Gr is an organic radical comprising one group which can be activated with actinic radiation; with the proviso that at least one of the two compounds (A) comprises aromatic or heterocyclic aromatic radical X and at least one comprises alkyl radical X; (B) oligo- and polyurethanes and/or oligo- and polyesters comprising two or three groups which can be activated with actinic radiation; (C) color and/or effect pigments; (D) waxes; (E)... |
| Injectable veterinary composition | 20090275662 | 20091105 |
| Injectable veterinary composition comprising a fluorinated chloramphenicol or thiamphenicol derivative and a solvent system comprising an ether of 1,2-ethanediol oligo- or polymers, and a pyrrolidone solvent.
... |
| Injectable veterinary composition | 20090275662 | 20091105 |
| Injectable veterinary composition comprising a fluorinated chloramphenicol or thiamphenicol derivative and a solvent system comprising an ether of 1,2-ethanediol oligo- or polymers, and a pyrrolidone solvent.
... |
| Methods of stimulating an immune response against prostate specific antigen | 20090263425 | 20091022 |
| The invention provides a prostate specific antigen oligo-epitope peptide (PSA-OP) that is useful as an immunogen in the prevention or treatment of prostatic cancer and in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines. In particular, the invention provides methods for eliciting an immune response against PSA comprising administering (i) a priming inoculation of a first recombinant virus encoding PSA-OP and (ii) one or more boosting inoculations of a second recombinant virus encoding PSA-OP, wherein the first and second recombinant viruses are from a different genus.
... |
| Phosphonic acid-containing blends and phosphonic acid-containing polymers | 20090220843 | 20090903 |
| The invention relates to blends and blend membranes from low-molecular hydroxymethylene-oligo-phosphonic acids R—C(PO3H2)x(OH)y and polymers, the group R representing any organic group and the polymers containing the following functional groups: cation exchanger groups or their nonionic precursors of the type SO2X, X=Hal, OH, OMe, NR1R2, OR1 with Me=any metal cation or ammonium cation, R1, R2=H or any aryl- or alkyl group, POX2, COX and/or basic groups such as primary, secondary or tertiary amino groups, imidazole groups, pyridine groups, pyrazole groups etc. and/or OH groups. Low molecular hydroxymethylene-oligo-phosphonic acids R—C(PO3H2)x(OH)y are preferred in which x=2 and y=1. The invention also relates to low-molecular hydroxymethylene-oligo-phosphonic acids R—C(PO3H2)2(OH)1 and polymers, wherein the group R of the hydroxymethylene-oligophosphonic acid contains an aliphatic or aromatic basic group which ionically interacts with... |
| Use of dietary fibres against muscle wasting | 20090203573 | 20090813 |
| A composition nutritional containing dietary fibres is useful for the treatment of muscle wasting, if the dietary fibre comprise at least 30 wt. % of galacto-oligosaccharides or other oligosaccharides having mainly anhydropyranose units, and having a chain length of 3-10 units. The composition may further contain other oligo- or polysaccharides, especially polysaccharides having a majority of anhydrofuranose units.
... |
| Tri- and tetra-oligo-saccharides suitable as agglutination agents for enteric pathogens | 20090186852 | 20090723 |
| Compositions which include a homotrimer, heterotrimer, homotetramer, and/or heterotetramer of a component such as pentose, hexose, an L or D isomer of a pentose or hexose, a β-form of a pentose or hexose, oxidized derivatives and mixtures of such compounds are disclosed as agglutination agents. The disclosed compositions are useful for agglutination of enteric pathogens and may be used for selectively controlling and regulating the microbial ecosystem in the gastrointestinal tract of a subject.
... |
| Compositions and methods for topical application and transdermal delivery of botulinum toxins | 20090087457 | 20090402 |
| Improved formulations for transdermal delivery of botulinum toxin are disclosed. The formulations include, for example, botulinum toxin non-covalently associated with a positively charged backbone having branching or efficiency groups. The formulations also include a partitioning agent, oligo-bridge, or polyanion bridge, and may optionally contain a viscosity modifying agent. The formulations are designed for topical application onto the skin of a patient and may be used to treat wrinkles, hyperhidrosis, and other health-related problems. Kits for administration are also described.
... |
| Preparation of sensors on oligo- or poly (ethylene glycol) films on silicon surfaces | 20090082222 | 20090326 |
| A sensor that includes a) a silicon (Si) substrate having a surface; and b) a monolayer of oligoethylene glycol (OEG) bonded to the surface via silicon-carbon bonds. Regions of the OEG monolayer distal to the surface are functionalized with a ligand serving as a recognition element for a bioanalyte. The ligand is covalently bonded in these regions as a cycloadduct of a 1,3-dipolar cycloaddition reaction. A method of making a silicon surface that recognizes a biological specimen includes 1) hydrosilylating with a mixture that includes an oligoethylene glycol (OEG) substituted with an alkene at one end of the OEG and capped at the opposing end of the OEG and an oligoethylene glycol (OEG) substituted with an alkene at one end of the OEG and an alkyne... |
| Method for de novo detection of sequences in nucleic acids: target sequencing by fragmentation | 20090075288 | 20090319 |
| The present invention provides a method for determining nucleic acid sequences of a template nucleic acid that requires no prior knowledge of the nucleic acid sequence present in the template nucleic acid. The method is based on combining information about the mass of a fragment, the mass of any one nucleotide and the combinations thereof, and the sequence specificity of a nucleotide cutter, either enzymatic or chemical cutter, to determine a sequence of a nucleic acid fragment. This method allows for de novo detection of sequences in a target nucleic acid without requiring any prior sequence information. This method is called Partial Sequencing by Fragmentation (PSBF) and it works by fragmenting a target into oligo- or polynucleotides whose masses or lengths are uniquely associated with known... |
| Photoacid generators for the synthesis of oligo-dna in a polymer matrix | 20090062149 | 20090305 |
| Such compounds are useful, for example, in fabricating arrays of polymers.
... |
| Ligation-based synthesis of oligonucleotides with block structure | 20090035823 | 20090205 |
| The present invention relates to a method of producing single-stranded nucleic acid molecules from oligo- or polynucleotides wherein each of said oligo- or polynucleotides has a predefined 5′ or 3′ terminus, comprising the steps of (a) annealing an adaptor oligonucleotide simultaneously or step by step to (aa) a first oligo- or polynucleotide; and (ab) a second oligo- or polynucleotide wherein the 5′-terminus of said adaptor oligonucleotide is complementary in sequence to the 5′ terminus of said first oligo- or polynucleotide and the 3′terminus of said adaptor molecule is complementary in sequence to the 3′ terminus of said second oligo- or polynucleotide; and optionally (a′) simultaneously with or subsequently to step (a) annealing at least one further adaptor oligonucleotide to free termini of said first or second... |
| Method for the continuous production of mono-, oligo- and/or polyborosilazanes that contain carbon | 20090030157 | 20090129 |
| The invention relates to a device and a method for producing mono-, oligo- and/or polyborosilazanes that contain carbon. According to said method (i) a one-component precursor compound is reacted with ammonia or an organic amino in an aminolysis step, (ii) a reaction mixture is extracted at least once from the aminolysis in a continuous extraction step using an organic solvent, (iii) ammonia or a phase containing organoamine that accumulates during the extraction process is discarded, recovered or at least partly recirculated and (iv) mono-, oligo- and/or polyborosilazanes containing carbon are obtained from the extraction phase containing the solvent.
... |
| Liposome compositions for treatment of hepatitis c | 20090017108 | 20090115 |
| In the present invention compositions and methods are described for treating patients with a hepatitis C viral infection typically using interferon-alpha and/or ribavirin which are incorporated into liposomes, wherein the liposomes typically contain at least one carbohydrate moiety on the surface, such as a mono-, di-, oligo-, or polysaccharide moiety or any combination thereof, for targeting to hepatocytes. Other liposome surface modifications are provided to enhance effectiveness of the compound(s) therein.
... |
| Composition and method for making oligo-benzamide compounds | 20090012141 | 20090108 |
| The present invention includes compound compositions and methods of making compounds that include an oligo-benzamide compound having at least two optionally substituted benzamides.
... |
| Monomers, oligomers and polymers comprising thiophene and selenophene | 20080303000 | 20081211 |
| The invention relates to novel mono-, oligo- and polymeric compounds comprising thiophene and selenophene, to their use as semiconductors or charge transport materials, in optical, electro-optical or electronic devices, and to optical, electro-optical or electronic devices comprising the novel compounds.
... |
| Novel iminecalixarene derivatives and aminocalixarene derivatives, method of preparation thereof, and self-assembled monolayer prepared by the method, fixing method of oligo-dna by using the self-assembled monolayer, and oligo-dna chip prepared by the met | 20080305477 | 20081211 |
| The present invention relates to novel iminecalixarene derivatives, method of preparation thereof, and self-assembled monolayer prepared by the method, fixing method of oligo-DNA by using the self-assembled monolayer, and oligo-DNA chip prepared by the method. Also, the present invention relates to novel aminocalixarene derivatives, method of preparation thereof, and self-assembled monolayer prepared by the method, fixing method of oligo-DNA wherein the oligo-DNA is voluntarily fixed by molecular recognition on said self-assembled monolayer in a liquid phase, and oligo-DNA chip prepared by the method.
... |
| Composition and method for the treatment of diseases affected by a peptide receptor | 20080300193 | 20081204 |
| The present invention includes peptidomimetic compound compositions and methods of making and using peptidomimetic compounds to modulate the activity of a peptide receptor for the treatment of one or more of hyperglycemia, insulin resistance, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia or other symptoms that relate to the function of the targeted receptor. The peptidomimetic includes an oligo-benzamide compound having at least three optionally substituted benzamides.
... |
| Alcohol free formulation of argatroban | 20080300272 | 20081204 |
| An aqueous formulation of argatroban and of related compounds is disclosed along with a reconstitutable formulation, each of which is substantially, if not totally alcohol free. The formulations are also substantially free, if not totally free, of mono-, di-, and oligo-saccharides. An especially preferred embodiment is a ready-to-administer 1 mg/ml injectable dosage form having argatroban, lactobionic acid, and methionine.
... |
| Reducing carbohydrate derivatives of adamantane amines, and synthesis and methods of use thereof | 20080300390 | 20081204 |
| The present invention relates to reducing carbohydrate derivatives of adamantane amines of Formula A or pharmaceutically acceptable salts, solvates or derivatives thereof, wherein R1, R2, R3, and R4 are together or separately H, F, methyl or lower alkyl, alkenyl, or alkynyl groups, and Z is derived from a mono-, di-, oligo-, or poly-saccharide that originally had an aldehyde carbonyl group. The present invention also relates to processes for the preparation of such adamantane amine derivatives, and uses of such derivatives. The compounds of the present invention are useful in the treatment of infections caused by Gram positive or Gram negative bacteria.
... |
| Hydrolytically stable isoelectric hydrogel compositions | 20080264793 | 20081030 |
| An hydrolytically stable isoelectric hydrogel material comprising a single isoelectric compound having a defined pI value from 1 to 12 being incorporated into a hydrogel formed by reacting an oligo- or polyhydroxy compound with the single iso-electric compound and a difunctional or oligofunctional crosslinker, wherein after incorporation of the single isoelectric compound into the hydrogel, the hydrogel material become's an ampholytic material.
... |
| Methods and kits for negative selection of desired nucleic acid sequences | 20080268508 | 20081030 |
| The present invention pertains to a method to isolate, separate, enrich or amplify a targeted nucleotide polymer such as mRNA through selective reverse transcription of the targeted polymer into cDNA from a sample comprising of chemically identical or similar polynucleotide polymers such as rRNA. The enrichment of the targeted nucleic acid such as mRNA is accomplished by blocking the reverse transcription of undesired rRNA while allowing unrestricted reverse transcription of the targeted polymer. The invention also embodies that the cleavage of the non-targeted nucleic acid such as rRNA bound to an oligonucleotide through enzymatic activity (RNase H). The invention further embodies methods and kits to accomplish the utility of the invention through the following steps 1) 3′ tailing of chemically identical or similar nucleotide polymers in... |
| Solid-state polymer electrolyte membrane, method for manufacture thereof and solid-state polymer electrolyte fuel cell therewith | 20080269360 | 20081030 |
| The present invention provides an inexpensive solid-state polymer electrolyte membrane to be used in a solid-state polymer electrolyte fuel cell, which can be manufactured by using inexpensive raw materials through a simpler chemical synthesis process, achieves good heat resistance and demonstrates superior proton conductivity at low humidity. A primary constituent of the solid-state electrolyte polymer film to be used in a solid-state polymer electrolyte fuel cell according to the present invention is a hyperbranched polymer having an acidic functional group such as sulfonic acid disposed at the terminal of a side chain thereof. The hyperbranched polymer may be, for instance, poly[(bis(oligo-ethylene glycol) benzoate)].
... |
| Method for the manufacture of oligo- and polyesters from a mixture of carboxylic acid obtained from suberin and/or cutin and use thereof | 20080262190 | 20081023 |
| The invention relates to a method for processing mixtures of carboxylic acids obtained as hydrolysis products of suberin and cutin, particularly suberin and cutin isolated from birch bark, to give oligo- and polyesters, or corresponding ester-ethers, as well as the use of the products thus obtained as lubricants, fuel components, plasticizers, surface active agents, environmentally friendly agents for modifying wood, binders in coatings, adhesives, printing inks and composites, further in various cosmetic applications.
... |
| Method to increase resistance against stain penetration of aqueous coating compositions | 20080245259 | 20081009 |
| The invention also relates to a method to increase stain resistance and penetration resistance of aqueous coating compositions which method comprises providing a coating composition which contain at least one pigment, at least one film-forming polymer in the form of an aqueous polymer dispersion and at least one anionic surfactant, wherein the anionic surfactant comprises at least 85% by weight, preferably at least 90% by weight, more preferably at least 95% by weight, based on the total weight of anionic surfactant in the coating composition, of at least one anionic surfactant S, which is selected from semi-esters of sulfuric acid or phosphoric acid with an alcohol, which alcohol carries at least one alkyl radical having from 8 to 30 carbon atoms or an alkyl substituted phenyl... |
| Cooling electronic components | 20080239776 | 20081002 |
| An illustrative embodiment of the invention provides an electronic power inverter for a traction motor and a coolant for the inverter. The power inverter comprises an aluminum component and the coolant is a non-aqueous dielectric liquid coolant composition including an inhibitor. The coolant consists essentially of a mixture of an oligo-(alkyl siloxane), such as hexamethyldisiloxane, and a monomer or oligomer of an alkyl ether alkylene glycol, such as 1-methoxy-2-propanol, and including an azole in an amount for inhibiting dissolution of the aluminum electronic component.
... |
| Protective hydrocolloid for active ingredients | 20080241320 | 20081002 |
| Partially deamidated rice endosperm protein or rice endosperm protein which is partially conjugated with mono-, di-, oligo- or polysaccharides is used as novel protective hydrocolloid for fat-soluble active ingredients and/or fat-soluble colorants. The present invention further includes compositions comprising that rice endosperm protein and at least one fat-soluble active ingredient/colorant, as well as their manufacture, that rice endosperm protein itself and its manufacture. These compositions are used for the enrichment, fortification and/or coloration of food, beverages, animal feed, personal care or pharmaceutical compositions. The present invention is directed to theses uses and to food, beverages, animal feed, personal care and pharmaceutical compositions containing such a rice endosperm protein and such a composition, respectively.
... |
| Rutile-based pigment and a method for the production thereof | 20080216711 | 20080911 |
| The invention covers a fine-particle, brilliant and strongly hiding rutile-based pigment that is devoid of any metal or reactive metal compounds relevant to mill abrasion detectable by application technology but whose particle-size in terms of particle diameters ranges from 50 to 1000 nm, for mono-, bi-, tri- or oligo-modal size distribution and a primary maximum ranges from 230 to 400 nm, wherein optionally for a bi- or poly-modal frequency distribution, a secondary maximum is less than 25% of the primary maximum between 400 and 1000 nm. The process for producing said pigment comprises treating an inorganic mixed-phase rutile structured oxide pigment by high-speed grinding in suspension in a ball grinding mill provided with a mechanically and chemically resistant coating until said particle-size and a substantially isometric... |
| Use of propenylphenyl glycosides for enhancing sweet sensory impressions | 20080220140 | 20080911 |
| for enhancing the sweet taste of a sweet-tasting substance or the sweet odour impression of a flavouring that produces a sweet odour impression.
... |
| Oligo-tetracenes, production and use thereof | 20080214838 | 20080904 |
| Also described is a method for preparing the referenced oligotetracenes, and use thereof as semiconductors in organic field-effect transistors (OFET's), organic light-emitting diodes (OLED's), sensors, and organic solar cells.
... |
| Composition for external use | 20080207560 | 20080828 |
| The composition for external use is prepared by blending (i) a phospholipid and (ii) a mono- or oligo-glycol ether, together with (iv) at least one bioactive component selected from the group consisting of hyaluronic acid, hyaluronic acid derivatives, vitamin A, vitamin A derivatives, vitamin C, specific vitamin C derivatives, xanthine derivatives, ubiquinones, and salts thereof.
... |
| Mono-,oligo- and polymers of thienothiazole | 20080200634 | 20080821 |
| The invention relates to novel mono-, oligo- and polymeric compounds comprising thienothiazole groups, to their use as semiconductors or charge transport materials, in optical, electro-optical or electronic devices, and to optical, electro-optical or electronic devices comprising the novel compounds.
... |
| Method for the controlled oxidation of polysaccharides | 20080194805 | 20080814 |
| The invention relates to a method for the controlled oxidation of oligo- and/or polysaccharides containing free —CH2OH primary hydroxyl groups, using an oxidising agent. The invention is characterised in that the oxidation reaction is performed in a densified fluid which is inert in relation to the oxidising agents employed. The invention is suitable for use, for example, in the food, paint, paper, textile, agricultural and pharmaceutical industries, in the medical, biomedical or paramedical fields, in the surgical field, in the cosmetic industry and as agents for the complexing or sequestering of metal ions, heavy metals and radioactive elements in the nuclear industry.
... |
| Method for waterproofing lignocellulosic materials | 20080187669 | 20080807 |
| (EN) The invention relates to a method for waterproofing lignocellulosic materials by impregnating the lignocellulosic material with a waterproofing agent, whereby the lignocellulosic material is impregnated with a hardenable aqueous composition before or during waterproofing, said composition containing at least one cross-linkable compound, selected from a) low-molecular weight compounds V, having at least two N-bonded groups of formula CH2OH, wherein R=hydrogen or C1-C4 alkyl, and/or one 1,2-bis-hydroxyethan-1,2-diyl group, bridging two nitrogen atoms, β) precondensates of the compound V and & gammad;) reaction products or mixtures of the compound V with at least one alcohol, selected from C1-C6 alkanols, C2-C6 polyols and oligo-C2-C4-alkylene glycols.
... |
| Method for the treatment of a sample containing biomolecules | 20080187924 | 20080807 |
| The invention generally provides a method for the sample preparation for a subsequent preparation, processing or analysis method of a sample containing an at least one species of nucleic acid and/or one species of protein, whereby the method comprises the following steps: A) providing a sample which contains at least one species of a nucleic acid and/or of a protein, B) contacting the sample with a fluid or solid composition to produce a fluid sample preparation, whereby the composition contains at least a nitrogenous compound, which is selected from the group consisting of a) polyamines, b) amino acids, and oligo- and polypeptides, c) nitrogenous heterocyclic compounds, including homo-older heteropolymeres, which comprise these nitrogenous compounds, d) amines of the type R1R2NR3, whereby R1, R2 and R3 are... |
| Novel guanosine triphosphate-binding protein-coupled receptor place6002312, its gene, and production and uses thereof | 20080171353 | 20080717 |
| The clone PLACE6002312 having a structure characteristic of G protein-coupled receptor was isolated from a human placental full-length cDNA library prepared by the oligo-capping method. Database search revealed that PLACE6002312 had the highest homology to HISTAMINE H2 RECEPTOR. Analysis for the expression of PLACE6002312 gene in human tissues revealed that the gene was expressed in various tissues, such as heart, liver, and ovary. In addition, histamine was found to be one of ligands for PLACE 6002312 by ligand-binding assay. Furthermore, a full-length cDNA for the mouse homolog of PLACE6002312 was isolated and the deduced amino acid sequence was revealed to comprise a structure characteristic of G protein-coupled receptor. PLACE6002312 can be used to screen for agonists and antagonists useful as pharmaceuticals and to diagnose various diseases... |
| Method for amplifying monomorphic-tailed nucleic acids | 20080161197 | 20080703 |
| The present teachings provide methods for amplifying a plurality of target nucleic acids. In some embodiments, a first oligo-dT-universal primer comprising a 3′ oligo-dT portion and a first 5′ universal portion is used to reverse transcribe a plurality of 3′ poly-A tail-containing nucleic acids. A poly-A tail is added to the 3′ end of the first strand products to form a two-tailed reaction product. The two-tailed reaction product is amplified in a PCR, wherein the PCR comprises the first oligo-dT-universal primer, and a second oligo-dT-universal primer, wherein the second oligo-dT-universal primer comprises a 3′ oligo-dT portion and a second 5′ universal portion, wherein the second 5′ universal portion of the second oligo-dT-universal primer comprises a different sequence than the first 5′ universal portion of the first... |
| Neisseria meningitidis lgtb los as adjuvant | 20080138359 | 20080612 |
| The present invention relates to Neisserial Lipo-Oligo-Saccharides (LOS) that comprise a tri-saccharide outer core that shows increased binding to the DC-SIGN receptor on dendritic cells, as a result of which the Neisserial LOS's of the invention have increased immunostimulatory activity. The tri-saccharide outer core of the Neiserial LOS's combined with a Lipid A moiety with reduced toxicity is useful as an adjuvant in vaccine preparations.
... |
| Low-viscosity microcapsule dispersions | 20080125552 | 20080529 |
| c) if appropriate, subsequent aftertreatment with at least one further aftertreatment reagent.
... |
| Nerve regeneration device | 20080125870 | 20080529 |
| Devices for use in the regeneration or repair of body tissue (such as nerves) comprise a multi-lumen scaffold and, optionally, an outer sheath. The tissue guidance conduits are preferably formed of biocompatible, biodegradable charged polymer hydrogels, particularly charged oligo-(polyethylene glycol)fumarate hydrogels. The outer sheath is formed of a stronger material than the scaffold and preferably comprises a region at each end for suturing the device in place. Methods for making tissue guidance conduits and for repairing tissue are also described.
... |
| Glycoconjugates and their use as potential vaccines against infection by shigella flexneri | 20080112951 | 20080515 |
| A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.
... |
| Method for de novo detection of sequences in nucleic acids: target sequencing by fragmentation | 20080096194 | 20080424 |
| The present invention provides a method for determining nucleic acid sequences of a template nucleic acid that requires no prior knowledge of the nucleic acid sequence present in the template nucleic acid. The method is based on combining information about the mass of a fragment, the mass of any one nucleotide and the combinations thereof, and the sequence specificity of a nucleotide cutter, either enzymatic or chemical cutter, to determine a sequence of a nucleic acid fragment. This method allows for de novo detection of sequences in a target nucleic acid without requiring any prior sequence information. This method is called Partial Sequencing by Fragmentation (PSBF) and it works by fragmenting a target into oligo- or polynucleotides whose masses or lengths are uniquely associated with known... |
| Alcohol free formulation of argatroban | 20080076798 | 20080327 |
| An aqueous formulation of argatroban and of related compounds is disclosed along with a reconstitutable formulation, each of which is substantially, if not totally alcohol free. The formulations are also substantially free, if not totally free, of mono-, di-, and oligo-saccharides. An especially preferred embodiment is a ready-to-administer 1 mg/ml injectable dosage form having argatroban, lactobionic acid, and methionine.
... |
| Method for preparing alkyl ethers and aryl ethers | 20080071084 | 20080320 |
| X and Y are independently of one another O, NH or NR1.
... |
| Conjugate of peo and double stranded nucleic acid | 20080064863 | 20080313 |
| A polyion complex is provided, comprising a double stranded nucleic acid containing a poly(ethylene oxide)-modified oligo- or poly-nucleotide and a polycationic compound, which is an effective delivery means of a gene to a target cell.
... |
| -conjugated mono-, oligo-and polymeric compounds, and photovoltaic cells comprising them | 20070289625 | 20071220 |
| in which: B and D, which are identical or different, each independently represent an aromatic carbon ring or an aromatic heterocycle which is optionally substituted. Use of the said compound in an optoelectronic device, such as a photovoltaic cell, a field-effect transistor or an electrochemical sensor. Photovoltaic cell comprising an active layer comprising an electron donor composed of the said compound.
... |
| Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions | 20070280910 | 20071206 |
| A probiotic composition including the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium. The composition may further include a carrier medium, such as fructo-oligo-saccharides (FOS), as incorporated in a dose form such as a pill, capsule, powder or sachet. The compositions of the invention may be usefully employed as health or nutritional supplements, food additives, or therapeutic agents for combating a wide variety of physiological disorders, such as irritable bowel syndrome, autism, and fibromyalgia.
... |
| Treatment of autism using probiotic composition | 20070280911 | 20071206 |
| A method of treating autism using a probiotic composition including the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium. The composition may further include a carrier medium, such as fructo-oligo-saccharides (FOS), as incorporated in a dose form such as a pill, capsule, powder or sachet. The compositions of the invention may be usefully employed as health or nutritional supplements, food additives, or therapeutic agents for combating a wide variety of physiological disorders.
... |
| Treatment of irritable bowel syndrome using probiotic composition | 20070280912 | 20071206 |
| A method of treating irritable bowel syndrome using a probiotic composition including the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium. The composition may further include a carrier medium, such as fructo-oligo-saccharides (FOS), as incorporated in a dose form such as a pill, capsule, powder or sachet. The compositions of the invention may be usefully employed as health or nutritional supplements, food additives, or therapeutic agents for combating a wide variety of physiological disorders.
... |
| Phosphoramidite compound and method for producing oligo-rna | 20070282097 | 20071206 |
| WG1 and WG2 are the same or different and each represents an electron-withdrawing group.
... |
| Method for detection of a sequence | 20070264652 | 20071115 |
| The present invention provides a novel method for detection of a sequence in a given sample, comprising the steps of isolating the target sequence from the given sample, providing a first and second probe comprising an oligo-nucleotide sequences complementary to respective ends of the target sequences and conjugated to a micro particle, contacting the probe with the target sequence under conditions to allow hybridization of the probes with the target sequence, exposing the target sequence to a reducing agent until appearance of a distinctive colour.
... |
| Photoacid generators for the synthesis of oligo-dna in a polymer matrix | 20070265366 | 20071115 |
| Such compounds are useful, for example, in fabricating arrays of polymers.
... |
| Mono-, oligo- and polythieno [3,2-b]thiophenes | 20070232812 | 20071004 |
| The invention relates to novel mono-, oligo- and polythieno[3,2-b]thiophenes, to their use as semiconductors or charge transport materials, in optical, electro-optical or electronic devices like for example liquid crystal displays, optical films, organic field effect transistors (FET or OFET) for thin film transistor liquid crystal displays and integrated circuit devices such as RFID tags, electroluminescent devices in flat panel displays, and in photovoltaic and sensor devices, and to field effect transistors, light emitting devices or ID tags comprising the novel polymers.
... |
| Preparation of nanometric arrays of biomolecules on oligo-or poly(ethylene glycol) films on silicon surfaces | 20070212555 | 20070913 |
| The present invention is generally directed to nanometric biomolecular arrays and to a novel approaches for the preparation of such nanoarrays, based on binding of biomolecules, such as avidin, to templates generated by lithographically-an-odizing biocompatible ultrathin films on silicon substrates using AFM anodization lithography. The present invention is also directed to methods of using such arrays.
... |
| Method for amplification of nucleic acids of low complexity | 20070178453 | 20070802 |
| The invention describes a method for amplifying nucleic acids, such as DNA with means of an enzymatic amplification step, such as a polymerase chain reaction, specified for template nucleic acids of low complexity, e.g. pre-treated DNA, like but not limited to DNA pre-treated with bisulfite is disclosed. The invention is based on the use of specific oligo-nucleotide primer molecules to solely amplify specific pieces of DNA. It is disclosed how to optimize the primer design for a PCR if the template DNA is of low complexity.
... |
| Ribonucleic acid compound and method of liquid-phase synthesis of oligonucleic acid compound | 20070172925 | 20070726 |
| (wherein B represents adenine, guanine, cytosine or uracil or a modified form thereof; R21 represents aryl which may be substituted or a monocyclic or bicyclic heterocyclic group which may be substituted; R20 represents H or alkyl which may be substituted; and R1 represents a protecting group which can be removed at 90% or more at a temperature in the range from 0° C. to 60° C. under acidic conditions at a pH value from 2 to 4 within 24 hours).
... |
| Methods and probes for identifying vulnerable plaque | 20070166231 | 20070719 |
| The present application discloses methods for detecting and localizing injuries in the vascular system of a subject, and in particular provides methods for detecting vulnerable or unstable plaques using oligo-deoxynucleotides (ODNs).
... |
| Vibrio cholerae o139 conjugate vaccines | 20070166315 | 20070719 |
| The disclosure pertains to conjugates of the capsular polysaccharide of Vibrio cholerae O139, or a structurally and/or immunologically related oligo- or poly-saccharide, and a carrier. These conjugates are useful as pharmaceutical compositions and/or vaccines to induce serum antibodies which have bactericidal (vibriocidal) activity against V. cholerae, in particular V. cholerae O139, and are useful to prevent, treat and/or reduce the severity of disease caused by V. cholerae infection, such as cholera. The present disclosure also relates to diagnostic tests for V. cholerae infection, and/or cholera caused by V. cholerae infection, using one or more of the oligo- or poly-saccharide-carrier conjugates or antibodies described above.
... |
| Fluorocarbon terminated oligo-and poly-carbonates as surface modifiers | 20070155854 | 20070705 |
| X1 and X2 are each independently of the other a direct bond or C1-C12alkylene, m is 1 to 10,000, and n is 0 to 10,000. These new compounds of the formula I are useful as reducers of surface energy for organic materials such as polycarbonates, polyesters or polyketones or their mixtures, blends or alloys. Polymers with such a reduced surface energy possess an “easy to clean”, “self-cleaning”“antisoiling”, “soil-release” “antigraffiti”, “oil resistance”, “solvent resistance”, “chemical resistance”, “self lubricating”, “scratch resistance”, “low moisture absorption” and “hydrophobic” surface.
... |
| Prostate specific antigen oligo-epitope peptide | 20070098691 | 20070503 |
| The invention is a prostate specific antigen oligo-epitope peptide which comprises more than one PSA epitope peptide, which conforms to one or more human HLA class I motifs. The prostate specific antigen oligo-epitope peptide in combination with various HLA-class I molecules or interactions with various T-cell receptors elicits PSA specific cellular immune responses. The prostate specific antigen oligo-epitope peptide is useful as an immunogen in the prevention or treatment of prostatic cancer, in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines.
... |
| Cosmetic oligo-alpha-olefin containing compound | 20070081959 | 20070412 |
| The disclosed invention relates to a cosmetic composition containing at least one branched oligo-α-olefin, characterized in that the side chains at one branch point at least are ethyl, propyl or longer branched alkyl chains, the branched oligo-α-olefin being obtainable by oligomerization of a) at least one branched α-olefin containing 5 to 18 carbon atoms, b) at least one linear α-olefin containing 4 to 10 carbon atoms, c) a mixture of a branched α-olefin containing 4 to 18 carbon atoms and a linear α-olefin containing 3 to 18 carbon atoms or d) a mixture of various branched α-olefins containing 4 to 18 carbon atoms and linear α-olefins containing 3 to 18 carbon atoms in the presence of a catalyst selected from the group consisting of organic acids,... |
| Compositions and methods for topical application and transdermal delivery of botulinum toxins | 20070077259 | 20070405 |
| Improved formulations for transdermal delivery of botulinum toxin are disclosed. The formulations include, for example, botulinum toxin non-covalently associated with a positively charged backbone having branching or efficiency groups. The formulations also include a partitioning agent, oligo-bridge, or polyanion bridge, and may optionally contain a viscosity modifying agent. The formulations are designed for topical application onto the skin of a patient and may be used to treat wrinkles, hyperhidrosis, and other health-related problems. Kits for administration are also described.
... |
| Additives for improving the cold flowability and lubricity of fuel oils | 20070062102 | 20070322 |
| R6 is C1-C200-alkyl or-alkenyl, n is from 1 to 100 and k is 1 or 2.
... |
| Ink carriers, phase change inks including same and methods for making same | 20070012217 | 20070118 |
| Disclosed is an ink carrier comprising an ester terminated oligo-amide material having a substantially low polydispersity. This ink carrier can be combined with a colorant to produce an ink composition.
... |
| System and method to obtain oligo-peptides with specific high affinity to query proteins | 20070015189 | 20070118 |
| The present invention relates to a method for constructing oligo-peptides with high binding affinity for a query protein.
... |
| Method for the manufacture of a pastel-white, highly opaque micro-particle rutile pigment, the therewith obtained rutile pigment and its utilization | 20070000411 | 20070104 |
| Described is a method for the manufacture of a pastel-white, highly opaque, micro-particle rutile pigment from a crude rutile, synrutile or from a slag-like rutile-type precursor characteristic for traditional titanium dioxide production from processing ilmenite into titanium dioxide. This method distinguishes itself in that the starter material in form of the crude rutile, synrutile or the slag-like rutile-type precursor is ground down in several stages in high efficiency mills without leaving any significant metallic fines, to a particle size of approximately 200 to 600 nm, whereby initially a dry pre-grinding step is performed and thereafter with high recorded grinding output a wet grinding step is performed in a final grinding phase. The ground-down product is dried and the obtained rutile pigment is calcinated in finely distributed... |
| Monomers, oligomers and polymers comprising thiophene and selenophene | 20060249712 | 20061109 |
| The invention relates to novel mono-, oligo- and polymeric compounds comprising thiophene and selenophene, to their use as semiconductors or charge transport materials, in optical, electro-optical or electronic devices, and to optical, electro-optical or electronic devices comprising the novel compounds.
... |
| Aqueous white pigment compositions | 20060252872 | 20061109 |
| Aqueous, white mineral pigment-based coating compositions (P) comprising (A) white mineral pigment particles (A1) and (A2), wherein, referred to the dry forms, (A1) are colloidal, non-porous, white mineral pigment particles of an average particle size in the range of 5 to 80 nm, wherein >99% of the particles are of a particle size <100 nm, and (A2) are micro-porous, white mineral pigment particles of an average particle size in the range of 0.5 to 25 μm, wherein >99% of the particles are of a particle size in the range of 0.1 to 100 μm, (B) a binder, and (C) a cationic, crosslinked polymer obtainable by exhaustive reaction of at least one crosslinking at least difunctional amine (G) and optionally a monofunctional anine (H) with a chloroterminated... |
| Process for producing a carbohydrate composition | 20060216401 | 20060928 |
| The present invention concerns a process for the production of a carbohydrate composition from lactose comprising a mixture of 10-50% galactose, 048% glucose, 1-25% fructose, 148% gluconic acid and 0-25% unconverted lactose and non-lactose di- and oligo-saccharides; and compositions produced by the process as well as food and drink containing the compositions.
... |
| Nucleic acid array consisting of selective monocyte macrophage genes | 20060216707 | 20060928 |
| The invention relates to an array comprising oligo- or poly-nucleotide probes, immobilized on a solid support. The array is characterized in that, sequences of a selection or all of the selective monocytic macrophagic genes given in Tables 1-6 are bonded on the surface. The array permits the diagnosis of rheumatoid arthritis and other chronic inflammatory diseases, a corresponding analysis of the efficacy of treatment and the monitoring of side-effects with the anti-tumor necrosis factor (TNF) therapy and thus permits the selection of the most effective therapy for each patient with rheumatoid arthritis. The invention further relates to a nucleic acid array for the prognosis and development of novel anti-TNF type medicaments and such medicaments with a mode of action in said regulatory circuit.
... |
| Reducing carbohydrate derivatives of adamantane amines, and synthesis and methods of use thereof | 20060211650 | 20060921 |
| The present invention relates to reducing carbohydrate derivatives of adamantane amines of Formula A or pharmaceutically acceptable salts, solvates or derivatives thereof, wherein R1, R2, R3, and R4 are together or separately H, F, methyl or lower alkyl, alkenyl, or alkynyl groups, and Z is derived from a mono-, di-, oligo-, or poly-saccharide that originally had an aldehyde carbonyl group. The present invention also relates to processes for the preparation of such adamantane amine derivatives, and uses of such derivatives. The compounds of the present invention are useful in the treatment of infections caused by Gram positive or Gram negative bacteria.
... |
| Growth factor complexes and modulation of cell migration and growth | 20060194292 | 20060831 |
| Isolated protein complexes are provided comprising growth factors such as IGF-I, IGF-II, VEGF or PDGF, or at least domains thereof that enable binding to and activation of both a growth factor receptor, and an integrin receptor-binding domain of vitronectin or fibronectin. These protein complexes may be in the form of oligo-protein complexes or single, synthetic proteins where the growth factor and vitronectin or fibronectin sequences are joined by a linker sequence. In particular forms, vitronectin or fibronectin sequences do not include a heparin binding domain and/or polyanionic domain. Also provided are uses of these protein complexes for stimulating or inducing cell migration and/or proliferation which may have use in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement and skin replenishment and treatment... |
| Preparation of a therapeutic composition | 20060177514 | 20060810 |
| Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system, comprises a unique peptide having 31 amino acids and another unique peptide having 21 amino acids and connected with an oligo-nucleotide through a diphosphodiester or diphosphodithioate ester linkage. The composition has a light absorption spectrum with typical absorption ratios of 1.998 at 260 nm/280 nm and 1.359 at 260 nm/230 nm.
... |
| Degradable biocompatible block copolymer | 20060178477 | 20060810 |
| Disclosed is a biocompatible block copolymer containing the polycondensation product of a diol and an additional component selected from the group of the same diol, an α,ω-dihydroxy-polyester or an α,ω-dihydroxy-polyether. Also disclosed are a medical implant containing the block copolymer, the use of said block copolymer for the production of a medical implant, a diol and a method for the production thereof. The diol may be obtained by transesterification of α,ω-dihydroxy-[oligo(3-(R)-hydroxybutyrate)-ethylene-oligo-(3-(R)-hydroxybutyrate)] with diglycolide. Transesterification is carried out, preferably, in the presence of a catalyst.
... |
| Compositions and systems for identifying and comparing expressed genes (mrnas) in eukaryotic organisms | 20060105362 | 20060518 |
| The invention comprises compositions and systems to identify and compare expressed genes in a given in vivo or in vitro RNA sample, as well as the relative difference in mRNA expression between two or more samples, where desired. Furthermore, the invention comprises compositions and systems to identify novel genes. The invention comprises, without limitation, one or more mRNA specific identimers for use in reverse transcription that themselves comprise an oligo-T nucleotide sequence (at the 5′ end) linked to a nucleotide sequence VNx (at the 3′ end) where the V nucleotide immediately adjacent to the oligo-T segment is not a T.
... |
| Catalysis of the cis/trans-isomerisation of secondary amide peptide compounds | 20060100130 | 20060511 |
| The present invention is based on the finding that the cis/trans isomerisation of secondary amide peptide bonds in oligo- and polypeptides can be catalytically promoted. This catalysis is effected by enzymes which are hereinafter called “secondary amide peptide bond cis/trans isomerases (APIases). It can be assumed that the APIase activity plays a central role in a number of pathophysiological processes. Thus, the invention relates to pharmaceutical compositions comprising substances which inhibit APIase activity.
... |
| Therapeutic composition and a method of coating implantable medical devices | 20060073183 | 20060406 |
| A therapeutic composition is provided including a polysaccharide or a cationic peptide dissolved in an organic substance. The polysaccharide can be heparin or a derivative of heparin. The cationic peptide can be L-arginine, oligo-L-arginine or poly-L-arginine. The organic substance can be formamide. A method of coating an implantable medical device is also provided, comprising applying the therapeutic composition to the device and allowing the organic substance to evaporate. The device can be a stent.
... |
